{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:13:31Z","timestamp":1778559211954,"version":"3.51.4"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007637","name":"Departamento Administrativo de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["110274558597"],"award-info":[{"award-number":["110274558597"]}],"id":[{"id":"10.13039\/100007637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejps.2020.105374","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T02:34:01Z","timestamp":1590201241000},"page":"105374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis"],"prefix":"10.1016","volume":"151","author":[{"given":"Andr\u00e9s-Felipe","family":"Villamizar-Mogotocoro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor Yamile","family":"Vargas-M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-8355","authenticated-orcid":false,"given":"Vladimir V.","family":"Kouznetsov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2020.105374_bib0001","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejmech.2017.07.004","article-title":"Design, synthesis and 2D QSAR study of novel pyridine and quinolone hydrazone derivatives as potential antimicrobial and antitubercular agents","volume":"138","author":"Abdelrahman","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/2051013615593891","article-title":"Recent advances in the development of vaccines for tuberculosis","volume":"3","author":"Ahsan","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"10.1016\/j.ejps.2020.105374_bib0003","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejps.2020.105374_bib0004","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00044-012-0222-8","article-title":"Coumarinyl pyrazole derivatives of INH: promising antimycobacterial agents","volume":"22","author":"Aragade","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejps.2020.105374_bib0005","series-title":"Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Synthesis and in vitro anti-mycobacterial activity of a novel anti-TB composition LL4858","author":"Arora","year":"2004"},{"key":"10.1016\/j.ejps.2020.105374_bib0006","unstructured":"Arora, S.K., Sinha, N., Jain, S., Upadhayaya, R.S., Jana, G., Ajay, S., Sinha, R.K., 2010. Pyrrole derivatives as antimycobacterial compounds. U.S. Patent No. 7,763,602. Washington, DC: U.S. Patent and Trademark Office."},{"key":"10.1016\/j.ejps.2020.105374_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/aps.2015.144","article-title":"Ion channels research in the post-genomic era","volume":"37","author":"Attali","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2020.105374_bib0008","first-page":"E9","article-title":"The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus","volume":"58","author":"Barberis","year":"2017","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.ejps.2020.105374_bib0009","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/AAC.43.8.1870","article-title":"Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. Antimicrob","volume":"43","author":"Bermudez","year":"1999","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejps.2020.105374_bib0010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0011","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.bmc.2019.02.025","article-title":"Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline","volume":"27","author":"Blaser","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0012","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1073\/pnas.1525047113","article-title":"Crystal structure and stability of gyrase\u2013fluoroquinolone cleaved complexes from Mycobacterium tuberculosis","volume":"113","author":"Blower","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2020.105374_bib0013","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.drudis.2016.11.014","article-title":"Target-based approaches for the discovery of new antimycobacterial drugs","volume":"22","author":"Borsari","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2020.105374_bib0014","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1016\/j.bmcl.2009.09.098","article-title":"Synthesis and antitubercular activity of 7-chloro-4-quinolinylhydrazones derivatives","volume":"19","author":"Cand\u00e9a","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2020.105374_bib0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021147","article-title":"Tuberculosis drug development: history and evolution of the mechanism-based paradigm","volume":"5","author":"Chakraborty","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejps.2020.105374_bib0016","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejmech.2016.08.034","article-title":"Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB","volume":"124","author":"Chaudhari","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijtb.2016.11.012","article-title":"Pyridines: multidrug-resistant tuberculosis (MDR-TB) inhibitors","volume":"64","author":"Chaudhari","year":"2017","journal-title":"Indian Journal of Tuberculosis"},{"key":"10.1016\/j.ejps.2020.105374_bib0018","unstructured":"Cheminformatics, M., 2011. Calculation of molecular properties and bioactivity score. URL http\/\/: www Molinspiration.com\/ (accessed Dec 2019)."},{"key":"10.1016\/j.ejps.2020.105374_bib0019","first-page":"1","article-title":"Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis.FEMS Immunol","volume":"63","author":"da Silva","year":"2011","journal-title":"Med. Microbiol"},{"key":"10.1016\/j.ejps.2020.105374_bib0020","series-title":"Advances in Microbial Physiology","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0065-2911(08)60016-8","article-title":"The envelope layers of mycobacteria with reference to their pathogenicity","author":"Daff\u00e9","year":"1997"},{"key":"10.1016\/j.ejps.2020.105374_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.thorsurg.2018.09.010","article-title":"The global fight against tuberculosis","volume":"29","author":"Daley","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.ejps.2020.105374_bib0022","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/1568026619666190304130218","article-title":"Targeting DNA gyrase to combat Mycobacterium tuberculosis: an update","volume":"19","author":"Das","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0023","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1016\/j.bmcl.2007.07.073","article-title":"Synthesis and antitubercular activity of lipophilic moxifloxacin and gatifloxacin derivatives","volume":"17","author":"de Almeida","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2020.105374_bib0024","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/prot.21376","article-title":"A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910","volume":"67","author":"de Jonge","year":"2007","journal-title":"Proteins Struct. Funct. Bioinforma"},{"key":"10.1016\/j.ejps.2020.105374_bib0025","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1021\/jm200305q","article-title":"Current status and research strategies in tuberculosis drug development: miniperspective","volume":"54","author":"Dover","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0026","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.mib.2018.02.006","article-title":"Priming the tuberculosis drug pipeline: New antimycobacterial targets and agents","volume":"45","author":"Evans","year":"2018","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.ejps.2020.105374_bib0027","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ejmech.2018.01.080","article-title":"Fluoroquinolone derivatives and their anti-tubercular activities","volume":"146","author":"Fan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0028","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/JCM.02775-15","article-title":"Gyrase mutations are associated with variable levels of fluoroquinolone resistance in Mycobacterium tuberculosis","volume":"54","author":"Farhat","year":"2016","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.ejps.2020.105374_bib0029","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-013-0009-3","article-title":"A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis","volume":"2","author":"Fox","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ejps.2020.105374_bib0030","article-title":"Recent developments on antimicrobial quinoline chemistry","author":"Gomez","year":"2013","journal-title":"Microb. Pathog. Strateg. Combat. Them Sci. Technol. Educ."},{"key":"10.1016\/j.ejps.2020.105374_bib0031","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1016\/j.ejmech.2010.09.024","article-title":"Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives","volume":"45","author":"Gon\u00e7alves","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0032","article-title":"Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2020.105374_bib0033","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4155\/fmc.11.79","article-title":"Diarylquinolines, synthesis pathways and quantitative structure\u2013activity relationship studies leading to the discovery of TMC207","volume":"3","author":"Guillemont","year":"2011","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0034","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1016\/j.rmed.2006.01.014","article-title":"Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis","volume":"100","author":"G\u00fclbay","year":"2006","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejps.2020.105374_bib0035","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/jac\/dkv054","article-title":"Bactericidal mode of action of bedaquiline","volume":"70","author":"Hards","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2020.105374_bib0036","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cmdc.201600441","article-title":"Structural simplification of bedaquiline: the discovery of 3-(4-(N, N -dimethylaminomethyl)phenyl)quinoline-derived antitubercular lead compounds","volume":"12","author":"He","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejps.2020.105374_bib0037","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.ejmech.2009.05.009","article-title":"Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid","volume":"44","author":"Hearn","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0038","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejps.2020.105374_bib0039","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: quinolone resistance","volume":"1354","author":"Hooper","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejps.2020.105374_bib0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejmech.2017.04.002","article-title":"Isoniazid derivatives and their anti-tubercular activity","volume":"133","author":"Hu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0041","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/cbdd.12949","article-title":"Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore-based virtual screening, molecular docking and molecular dynamics studies","volume":"90","author":"Islam","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejps.2020.105374_bib0042","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41586-019-1315-z","article-title":"Large-scale chemical\u2013genetics yields new M. tuberculosis inhibitor classes","volume":"571","author":"Johnson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2020.105374_bib0043","first-page":"396","article-title":"New inhibitors of Mycobacterium tuberculosis identified using systems chemical biology","author":"Johnson","year":"2018","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejps.2020.105374_bib0044","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.ejps.2020.105374_bib0045","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1007\/s00044-011-9948-y","article-title":"Isoniazid: the magic molecule","volume":"21","author":"Judge","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejps.2020.105374_bib0046","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tube.2014.10.003","article-title":"Future target-based drug discovery for tuberculosis?","volume":"94","author":"Kana","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejps.2020.105374_bib0047","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.biopha.2014.10.007","article-title":"Quinoline: a promising antitubercular target","volume":"68","author":"Keri","year":"2014","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.ejps.2020.105374_bib0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijantimicag.2012.09.012","article-title":"Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase","volume":"41","author":"Khan","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2020.105374_bib0049","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09657","article-title":"The challenge of new drug discovery for tuberculosis","volume":"469","author":"Koul","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2020.105374_bib0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit C of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejps.2020.105374_bib0051","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejmech.2014.05.005","article-title":"Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation","volume":"81","author":"Kumar","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0052","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nsmb.1604","article-title":"Structural insight into the quinolone\u2013DNA cleavage complex of type IIA topoisomerases","volume":"16","author":"Laponogov","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejps.2020.105374_bib0053","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/emmm.201201772","article-title":"Tuberculosis drug discovery in the post\u2010post\u2010genomic era","volume":"6","author":"Lechartier","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejps.2020.105374_bib0054","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead-and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejps.2020.105374_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tube.2017.12.002","article-title":"Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance","volume":"109","author":"Lohrasbi","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejps.2020.105374_bib0056","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3998\/ark.5550190.0008.f18","article-title":"Evaluation of anti-tubercular activity of nicotinic and isoniazid analogues","volume":"15","author":"Lourenco","year":"2007","journal-title":"Arkivoc"},{"key":"10.1016\/j.ejps.2020.105374_bib0057","unstructured":"Luca, S., Mihaescu, T., 2013. History of BCG Vaccine."},{"key":"10.1016\/j.ejps.2020.105374_bib0058","first-page":"711","article-title":"Interplay between mutations and efflux in drug resistant clinical isolates of mycobacterium tuberculosis. Front","volume":"8","author":"Machado","year":"2017","journal-title":"Microbiol"},{"key":"10.1016\/j.ejps.2020.105374_bib0059","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0014-827X(01)01097-7","article-title":"Synthesis and antimycobacterial activity of [5-(pyridin-2-yl)-1,3,4-thiadiazol-2-ylthio] acetic acid arylidene-hydrazide derivatives","volume":"56","author":"Mamolo","year":"2001","journal-title":"Il Farm"},{"key":"10.1016\/j.ejps.2020.105374_bib0060","first-page":"354","article-title":"A review on quinoline hydrazone derivatives as a new class of potent antitubercular and anticancer agents","volume":"6","author":"Mandewale","year":"2017","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"10.1016\/j.ejps.2020.105374_bib0061","first-page":"1624","article-title":"Design, synthesis, and pharmacological evaluation of mefloquine\u2010based ligands as novel antituberculosis agents","volume":"2","author":"Mao","year":"2007","journal-title":"ChemMedChem Chem. Enabling Drug Discov."},{"key":"10.1016\/j.ejps.2020.105374_bib0062","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bmcl.2009.11.105","article-title":"Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs","volume":"20","author":"Mao","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2020.105374_bib0063","first-page":"289","article-title":"InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system","volume":"146","author":"Marrakchi","year":"2000","journal-title":"FAS-II. Microbiology"},{"key":"10.1016\/j.ejps.2020.105374_bib0064","first-page":"E241","article-title":"The never-ending story of the fight against tuberculosis: from Koch's bacillus to global control programs","volume":"59","author":"Martini","year":"2018","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.ejps.2020.105374_bib0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejmech.2014.04.077","article-title":"Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity","volume":"81","author":"Martins","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0066","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.bmc.2016.01.011","article-title":"Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors","volume":"24","author":"Medapi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0067","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.bmc.2015.03.004","article-title":"Design and synthesis of novel quinoline\u2013aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors","volume":"23","author":"Medapi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.06.032","article-title":"4-aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation","volume":"103","author":"Medapi","year":"2015","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.ejps.2020.105374_bib0069","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2017.03.028","article-title":"Anti-tubercular drug discovery: in silico implications and challenges","volume":"104","author":"Mehra","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2020.105374_bib0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/bioinformatics\/bts641","article-title":"MycPermCheck: the Mycobacterium tuberculosis permeability prediction tool for small molecules","volume":"29","author":"Merget","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejps.2020.105374_bib0071","doi-asserted-by":"crossref","unstructured":"Moadebi, S., Harder, C.K., Fitzgerald, M.J., Elwood, K.R., Marra, F., 2007. Fluoroquinolones for the treatment of pulmonary tuberculosis: Drugs67, 2077\u20132099.","DOI":"10.2165\/00003495-200767140-00007"},{"key":"10.1016\/j.ejps.2020.105374_bib0072","unstructured":"Molsoft. Molecules in silico. URLhttps:\/\/www.molsoft.com\/index.html."},{"key":"10.1016\/j.ejps.2020.105374_bib0073","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-14-S1-S2","article-title":"Vaccine against tuberculosis: what's new?","volume":"14","author":"Montagnani","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejps.2020.105374_bib0074","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature02759","article-title":"The challenge of emerging and re-emerging infectious diseases","volume":"430","author":"Morens","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejps.2020.105374_bib0075","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1074\/jbc.M113.529164","article-title":"Fluoroquinolone-Gyrase-DNA Complexes: two modes of drug binding","volume":"289","author":"Mustaev","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0076","unstructured":"MycPermCheck: The Mycobacterium tuberculosis permeability prediction tool for small molecules. URLhttp:\/\/www.mycpermcheck.aksotriffer.pharmazie.uni-wuerzburg.de\/."},{"key":"10.1016\/j.ejps.2020.105374_bib0077","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3390\/molecules22091457","article-title":"Mechanochemical synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity","volume":"22","author":"Oliveira","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2020.105374_bib0078","unstructured":"OSIRIS Integrated Testing Strategy tool. URLhttp:\/\/osiris.simpple.com\/OSIRIS-ITS\/itstool.do."},{"key":"10.1016\/j.ejps.2020.105374_bib0079","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/S0040-4020(01)87332-4","article-title":"Conformational behaviour and E\/Z isomerization of N-acyl and N-aroylhydrazones","volume":"42","author":"Palla","year":"1986","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejps.2020.105374_bib0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1023\/A:1012188625088","article-title":"Polar molecular surface properties predict the intestinal absorption of drugs in humans","volume":"14","author":"Palm","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2020.105374_bib0081","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ejmech.2010.01.028","article-title":"Thiosemicarbazones, semicarbazones, dithiocarbazates and hydrazide\/hydrazones: Anti\u2013 Mycobacterium tuberculosis activity and cytotoxicity","volume":"45","author":"Pavan","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0082","doi-asserted-by":"crossref","unstructured":"Pontali, E., Sotgiu, G., D'Ambrosio, L., Centis, R., Migliori, G.B., 2016. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence.","DOI":"10.1183\/13993003.01891-2015"},{"key":"10.1016\/j.ejps.2020.105374_bib0083","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejps.2020.105374_bib0084","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ejps.2020.105374_bib0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fmolb.2017.00075","article-title":"Targeting DNA replication and repair for the development of novel therapeutics against tuberculosis","volume":"4","author":"Reiche","year":"2017","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejps.2020.105374_bib0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2020.105374_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00044-017-1970-2","article-title":"Synthesis of new 7-chloro-4-phenoxyquinoline analogues as potential antitubercular agents","volume":"27","author":"Salve","year":"2018","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejps.2020.105374_bib0088","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bmcl.2017.02.031","article-title":"Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors","volume":"27","author":"Salve","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2020.105374_bib0089","series-title":"Annual Reports in Medicinal Chemistry","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/B978-0-12-396492-2.00021-7","article-title":"Nonfluoroquinolone-based inhibitors of mycobacterial type II topoisomerase as potential therapeutic agents for tb","author":"Shirude","year":"2012"},{"key":"10.1016\/j.ejps.2020.105374_bib0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3109\/14756366.2014.930454","article-title":"Quinoline and quinolones: promising scaffolds for future antimycobacterial agents","volume":"30","author":"Singh","year":"2015","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0091","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.bmc.2014.12.060","article-title":"Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis","volume":"23","author":"Singh","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0092","first-page":"4502","article-title":"Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. Bioorg. Med. Chem","volume":"15","author":"Sriram","year":"2005","journal-title":"Lett"},{"key":"10.1016\/j.ejps.2020.105374_bib0093","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tube.2017.04.002","article-title":"Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis","volume":"105","author":"Srivastava","year":"2017","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejps.2020.105374_bib0094","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1074\/jbc.M808106200","article-title":"An oxyferrous heme\/protein-based radical intermediate is catalytically competent in the catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG)","volume":"284","author":"Suarez","year":"2009","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.ejps.2020.105374_bib0095","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.bmc.2018.02.026","article-title":"Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles","volume":"26","author":"Sutherland","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0096","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1128\/CMR.18.1.81-101.2005","article-title":"Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis","volume":"18","author":"Takayama","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2020.105374_bib0097","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1039\/C5MD00589B","article-title":"Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway","volume":"7","author":"Tantry","year":"2016","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejps.2020.105374_bib0098","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1016\/j.bmcl.2016.10.082","article-title":"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads","volume":"26","author":"Tanwar","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2020.105374_bib0099","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1016\/j.ejmech.2011.07.033","article-title":"Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents","volume":"46","author":"Thomas","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0100","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1021\/acsmedchemlett.7b00196","article-title":"6-Cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis","volume":"8","author":"Tong","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2020.105374_bib0101","first-page":"474","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect. Genet","volume":"45","author":"Unissa","year":"2016","journal-title":"Evol"},{"key":"10.1016\/j.ejps.2020.105374_bib0102","first-page":"4681","article-title":"Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Bioorg. Med","volume":"17","author":"Upadhayaya","year":"2009","journal-title":"Chem"},{"key":"10.1016\/j.ejps.2020.105374_bib0103","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1039\/b924102g","article-title":"Conformationally-constrained indeno[2,1- c]quinolines \u2013 a new class of anti-mycobacterial agents","volume":"8","author":"Upadhayaya","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0104","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ejmech.2011.01.053","article-title":"Synthesis and antimycobacterial activity of prodrugs of indeno [2,1- c] quinoline derivatives","volume":"46","author":"Upadhayaya","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ejmech.2010.01.024","article-title":"Novel quinoline and naphthalene derivatives as potent antimycobacterial agents","volume":"45","author":"Upadhayaya","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2020.105374_bib0106","first-page":"2830","article-title":"Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg. Med","volume":"17","author":"Upadhayaya","year":"2009","journal-title":"Chem"},{"key":"10.1016\/j.ejps.2020.105374_bib0107","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1080\/07391102.2018.1498806","article-title":"Design of novel quinoline-aminopiperidine derivatives as Mycobacterium tuberculosis (MTB) GyrB inhibitors: an in-silico study","volume":"37","author":"Wang","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejps.2020.105374_bib0108","first-page":"2062","article-title":"An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect","volume":"64","author":"Wayne","year":"1996","journal-title":"Immun"},{"key":"10.1016\/j.ejps.2020.105374_bib0109","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/518665","article-title":"HIV infection and multidrug-resistant tuberculosis\u2014the perfect storm","volume":"196","author":"Wells","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejps.2020.105374_bib0110","first-page":"114","article-title":"Isoniazid, the frontline of resistance in Mycobacterium tuberculosis. McGill J","volume":"6","author":"Whitney","year":"2002","journal-title":"Med"},{"key":"10.1016\/j.ejps.2020.105374_bib0111","series-title":"Global tuberculosis report 2019. 2019","year":"2019"},{"key":"10.1016\/j.ejps.2020.105374_bib0112","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/phar.1482","article-title":"Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis","volume":"34","author":"Worley","year":"2014","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.ejps.2020.105374_bib0113","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1021\/ja9639731","article-title":"The requirement for manganese and oxygen in the isoniazid-dependent inactivation of Mycobacterium tuberculosis enoyl reductase","volume":"119","author":"Zabinski","year":"1997","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.ejps.2020.105374_bib0114","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.5588\/ijtld.15.0389","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015","volume":"19","author":"Zhang","year":"2015","journal-title":"Inter. J. Tuberc. Lung Dis."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720301639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098720301639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:56:31Z","timestamp":1778558191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720301639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":114,"alternative-id":["S0928098720301639"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105374","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyridine and quinoline molecules as crucial protagonists in the never-stopping discovery of new agents against tuberculosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2020.105374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105374"}}